Brief Title
Medication Exposure in Older Patients With Constitutional Hemorrhagic Disease
Official Title
Medication Exposure in Older Patients (AGEd > 65 Years) With Constitutional HEMORRHagic Disease (Haemophilia or Willebrand Disease).
Brief Summary
The improvements observed in the care of patients with hemophilia or Willebrand disease have led to an increase in their life expectancy, which today approaches that of the general population. This increase in life expectancy leads in these patients to the development of comorbidities related to aging (cardiovascular and neurological diseases, cancers and kidney diseases) (e.g "Franchini & Mannuccio", BJH, 2009). The care of these comorbidities represents a new challenge for the medical teams. Toward multiple comorbidities, polypharmacy is often associated. Many studies about medication exposure and management in older patients were published but no study was conducted to explore the medication management of older patients with hemophilia or Willebrand disease.
Study Type
Observational
Primary Outcome
Potentially inappropriate medication (PIM) prevalence using EU-(7) PIM list.
Condition
Hemophilia
Intervention
Telephone interview
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Other
Estimated Enrollment
142
Start Date
July 22, 2020
Completion Date
January 29, 2021
Primary Completion Date
January 29, 2021
Eligibility Criteria
Inclusion Criteria: - Community-dwelling patients over 65 years with hemophilia (A or B) - Community-dwelling patients over 65 years with Willebrand disease (Type1, 2 and 3, rate <30%) Exclusion Criteria: - Patients without phone number - Non French speaking patients
Gender
All
Ages
N/A - 65 Years
Accepts Healthy Volunteers
No
Contacts
, ,
Location Countries
France
Location Countries
France
Administrative Informations
NCT ID
NCT04282486
Organization ID
69HCL20_0086
Responsible Party
Sponsor
Study Sponsor
Hospices Civils de Lyon
Study Sponsor
, ,
Verification Date
July 2021